Roche Boasts Of Tecentriq's Broad Potential In 3Q Earnings Update

Roche CEO Severin Schwan called recently launched PD-L1 drug Tecentriq's CHF77m sales figure impressive when presenting the company's third-quarter earnings on Oct. 20. Roche also spotlighted its "comprehensive" immuno-oncology portfolio which is producing "quantity as well as quality" with five product launches in 12 months.

Even as the third programmed-death inhibitor to market, oncology powerhouse Roche reported sales of CHF77m ($77.6m) for its immunotherapy Tecentriq in its first full quarter of sales, with “strong initial uptake.”

Tecentriq (atezolizumab) became the first PD-L1 product on the market after winning FDA approval in May for use in bladder...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business